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Abstract: 
A series of novel 4-isochromanone compounds bearing N-benzyl pyridinium 
moiety were designed and synthesized as acetylcholinesterase (AChE) inhibitors. The 
biological evaluation showed that most of the target compounds exhibited potent 
inhibitory activities against AChE. Among them, compound 1q possessed the 
strongest anti-AChE activity with an IC50 value of 0.15 nM and high AChE/BuChE 
selectivity (SI >5000). Moreover, compound 1q had low toxicity in normal nerve 
cells and was relatively stable in rat plasma. Together, the current finding may provide 
a new approach for the discovery of novel anti-Alzheimer’s disease agents. 
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benzyl pyridine 
 
Alzheimer’s disease (AD) is a progressive and neurodegenerative disease 
characterized by dementia, memory loss and other cognitive impairments, which 
affects millions of elder people around the world
1,2
. Although many factors contribute 
to this disease, its etiology and pathogenesis remain unclear until now. Studies have 
shown that several factors, including obvious reduction in cholinergic neurons
3
, 
accumulation and aggregation of β-amyloid peptide4 (Aβ) and oxidative stress5 play 
significant roles in the development of AD
6
. These physiological changes in turn lead 
to the current strategies for the treatment and prevention of AD. Among them, 
increasing levels of acetylcholine (Ach) through inhibition of cholinesterase (ChEs) 
has been used most frequently to treat AD
7
. Up to now, several acetylcholinesterase 
inhibitors such as donepezil, rivastigmine and galantamine have been approved and 
widely used for the treatment of AD
8
. There is evidence that two binding sites exist in 
AChE according to the crystal structure of the AChE of the eel, including the catalytic 
active site (CAS) and the peripheral anionic site (PAS)
9
. Therefore, it is meaningful to 
design dual-site inhibitors, which can interact with both the CAS and PAS to prevent 
AD.  
It has been reported that N-benzyl pyridinium moiety was introduced into a series 
of aromatic scaffolds and emerged as an essential structure for some inhibitors of 
AchE
10
 (Figure 1). In our previous studies, using donepezil as a template
11
, a series of 
dual-site AChE inhibitors were synthesized by introducing N-benzyl pyridinium 
moiety into the natural product XJP (Figure 1). Among these compounds, the most 
potent compound 1 showed good AChE inhibitory activity (IC50  value : 8.9 nM) and 
excellent AChE/BuChE selectivity (SI >230)
11
. The structure-activity relationships 
(SARs) studies demonstrated that benzyl pyridine, 4-isochromanone skeleton and 
nitrogen ion were essential for the activity against AChE. Moreover, the activity was 
maintained or increased by introducing the fluorine or chlorine to the benzyl group. 
Other groups introduced to the para-position of the benzyl group diminished the 
inhibitory activity remarkably. However, the effect of methoxy group at 
4-isochromanone skeleton on the AChE inhibitory activity was undefined. Besides, 
the preferred position of fluorine or chlorine on benzyl group and the importance of 
α,β-unsaturated ketone to the AChE inhibitory activity should be explored logically.  
Figure 1. Discovery of potent AchE inhibitor 1 and the design of its derivatives 
 
Inspired by our previous promising study and preliminary SARs, we embarked on 
the second-round design to accomplish the SARs and find more potent AChE 
inhibitors. Herein, a series of novel AChE inhibitors bearing 4-isochromanone moiety 
were further designed and synthesized using compound 1 as the lead compound. The 
ChEs inhibitory activities and selectivity of target compounds were also evaluated. 
Moreover, the neurotoxicity and plasma stability studies of potent compounds were 
disclosed in this research.  
 
 Scheme 1 Reagents and conditions: (a) K2CO3, H2O/toluene, r.t., 30 min; (b) 
NaOMe, MeOH, r.t. then H2O, 95% yield over two steps; (c) Oxalyl chloride, then N, 
O-Dimethyl hydroxylamine hydrochloride, 80% yield; (d) t-BuLi, THF, -78 °C, 1-5 
min, 70% yield; (e) K2CO3, MeOH, r.t., 4 h, 60% yield; (f) CH3CN, reflux, 1 h, 
60%-80% yields. 
 
The synthetic route of target compounds was shown in Schemes 1-2. Based on our 
previously developed method for the construction of 4-isochromanone with Weinreb 
amide
12
, we successfully completed the synthesis of 4-isochromanone skeleton to get 
the compound 7, which reacted with pyridine formaldehyde to yield the intermediate 
9 in the presence of K2CO3. Target compounds 1a-1r were obtained after the 
nucleophilic substitution of compound 9.  
 
Scheme 2 Reagents and conditions: (a) H2/Pd-C, 0.7 Mpa, r.t., overnight, 70% yield; 
(b) Dess-Martin reagent, r.t. 85% yield; (c) CH3CN, reflux, 1 h, 60%-80% yields. 
 The intermediate 9 was hydrogenated with Pd-C as a catalyst at the pressure of 0.7 
MPa to afford compound 11, which was oxidized with Dess-Martin oxidizing reagent 
to yield compound 12. Compounds 1s-1v were obtained by the reaction of compound 
12 with various substituted benzyl bromide. 
 
Table 1. Inhibition of ChEs by target compounds, and their selectivity index 
 
compound R1 R2 R3  R4 R5 R6 IC50 (nM) Selectivity 
Index AChE BuChE 
1        8.93±0.4 2.07±0.06 232 
1a H OCH3 OCH3 = F F H 91.80±3.92 902.13±37.92 9.8 
1b H OCH3 OCH3 = F H F 25.63±1.09 438.92±20.14 17.1 
1c H OCH3 OCH3 = F Cl H 97.27±4.82 5580±21 57.4 
1d H OCH3 OCH3 = F H Cl 23.44±1.12 728.61±35.43 31.1 
1e H OCH3 OCH3 = H CF3 H 48.69±2.31 4280±12 87.9 
1f H OCH3 OCH3 = H H CF3 70.03±3.19 592.36±28.18 8.5 
1g H OCH3 H = F F H 1023±45 59120±2580 57.8 
1h H OCH3 H = F H F 5.42±0.25 950±4.5 175.3 
1i H OCH3 H = F Cl H 96.82±4.32 3860±130 39.9 
1j H OCH3 H = F H Cl 5.09±0.23 1210±48 237.7 
1k H H H = H H H 31.92±1.52 2020±90 63.3 
1l H H H = F H H 30.57±1.32 1130±43 36.9 
1m H H H = H F H 28.22±1.28 2540±90 90.0 
1n H H H = H H F 33.32±1.48 2410±80 72.3 
1o OCH3 OCH3 H = H H H 0.29±0.013 968.68±48.21 3340.3 
1p OCH3 OCH3 H = H F H 0.34±0.015 329.04±15.12 967.8 
1q OCH3 OCH3 H = F H H 0.15±0.007 885.53±43.17 5903.5 
1r OCH3 OCH3 H = H H F 0.44±0.021 798.35±37.29 1814.4 
1s H OCH3 OCH3 - H H H 27.13±1.29 4306±25 158.7 
1t H OCH3 OCH3 - F H H 161.28±8.00 4920±18 30.6 
1u H OCH3 OCH3 - H F H 88.95±4.23 3210±15 36.1 
1v H OCH3 OCH3 - H H F 44.38±2.33 4560±18 102.7 
donepezil        37.54±1.92 3410±150 90.8 
 
MATERIALS AND METHODS 
Chemistry 
NMR experiments were run on a Bruker-ACF-300 and calibrated using TMS or 
residual deuterated solvent as an internal reference (CDCl3:7.26 ppm for 
1
H NMR and 
77.16 ppm for 
13
C NMR or DMSO-d6: 2.50 ppm for 
1
H NMR and 39.5 ppm for 
13
C 
NMR). HRMS was performed on an Agilent 6530 Q-TOF mass spectrometer, and 
ESI-MS was carried out on an Agilent 6120 mass spectrometer. All commercial 
reagents and anhydrous solvents were obtained from commercial sources and were 
used without further purification unless otherwise specified. 
 
General procedure for preparation of compounds 
Compound 9 or 12 was dissolved in acetonitrile, then substituted bromobenzene 
was added. The mixture was refluxed at 80 
o
C for 1 h. The yellow solid precipitated 
and the target compound were obtained by filtration. 
(Z)-1-(2,4-difluorobenzyl)-4-((7,8-dimethoxy-4-oxoisochroman-3-ylidene)methyl)p
yridinium bromide (1b)  
Yellow solid; 
1
H NMR (300 MHz, DMSO-d6) δ: 9.047 (d, J = 5.64 Hz, 2H), 8.45 (d, 
J = 5.64 Hz, 2H), 7.80 (m, 2H), 7.40 (m, 3H), 6.99 (s, 1H), 5.91 (s, 2H), 5.61 (s, 2H), 
3.98 (s, 3H), 3.83 (s, 3H); 
13
C NMR (75 MHz, DMSO-d6) δ: 176.80, 157.54, 156.04, 
150.28, 144.17, 142.32, 133.03, 132.46, 126.69, 124.44, 121.07, 117.84, 113.25, 
112.52, 112.23, 105.05, 104.85, 104.71, 104.37, 63.75, 60.31, 56.31; MS-ESI: (ESI, 
pos.ion) m/z: 503.05. HRMS-ESI: [M-Br
-
]
+
 calcd. For C24H19F2NO4: 424.1355, found: 
424.1362. 
  
(Z)-1-(3-chloro-4-fluorobenzyl)-4-((7,8-dimethoxy-4-oxoisochroman-3-ylidene)me
thyl)pyridinium (1c) 
Yellow solid; 
1
H NMR (300 MHz, DMSO-d6) δ: 9.08 (d, J = 6.78 Hz, 2H), 8.43 (d, 
J = 6.78 Hz, 2H), 7.94 (dd, J1= 1.98 Hz, J2= 7.08 Hz, 1H), 7.85 (d, J = 8.76 Hz, 1H), 
7.76 (m, 1H), 7.54 (t, J = 8.74 Hz, 1H), 7.32 (d, J = 8.79 Hz, 2H), 6.99 (s, 1H), 5.77 (s, 
2H), 5.61 (s, 2H), 3.97 (s, 3H) , 3.82 (s, 3H); 
13
C NMR (75 MHz, DMSO-d6) δ:176.87, 
157.57, 156.00, 150.16, 144.04, 132.49, 132.11, 130.07, 129.97, 126.81, 125.29, 
124.46, 121.11, 117.79, 117.51, 113.28, 104.91, 63.74, 60.87, 60.33, 56.32; MS-ESI: 
(ESI, pos.ion): 440.1; HRMS-ESI: [M-Br
-
]
+
 calcd. For C24H21ClFNO4: 440.1059, 
found: 442.1217. 
 
(Z)-1-(2-chloro-4-fluorobenzyl)-4-((7,8-dimethoxy-4-oxoisochroman-3-ylidene)me
thyl)pyridinium bromide (1d) 
Yellow solid; 1H NMR (300 MHz, DMSO-d6) δ:8.95 (d, J = 6.90 Hz, 2H), 8.44 (d, 
J = 6.90 Hz, 2H), 7.86 (d, J = 8.76 Hz, 1H), 7.64 (m, 2H), 7.40 (m, 2H), 7.01 (s, 1H), 
5.89 (s, 2H), 5.61 (s, 2H), 3.97 (s, 3H) , 3.82 (s, 3H); 
13
C NMR (75 MHz, DMSO-d6) 
δ: 176.83, 157.58, 156.16, 150.40, 144.33, 133.49, 133.37, 132.45, 126.60, 124.47, 
121.09, 117.78, 117.44, 115.43, 115.15, 113.28, 104.83, 63.77, 60.32, 59.67, 56.32; 
MS-ESI: (ESI, pos.ion): 519.02; HRMS-ESI: [M-Br
-
]
+
 calcd. For C24H19ClFNO4: 
440.1059, found: 440.1055. 
 
(Z)-4-((7,8-dimethoxy-4-oxoisochroman-3-ylidene)methyl)-1-(3-(trifluoromethyl)b
enzyl)pyridinium bromide (1e) 
Yellow solid; 
1
H NMR (300 MHz, DMSO-d6) δ: 9.21 (d, J = 6.51 Hz, 2H), 8.46 (d, 
J = 6.51 Hz, 2H), 8.09 (s, 1H), 7.93-7.81 (m, 3H), 7.72 (t, J = 7.71 Hz, 1H), 7.33 (d, J 
= 8.79 Hz, 1H), 6.99 (s, 1H), 5.97 (s, 2H), 5.63, (s, 2H), 3.98 (s, 3H) , 3.83 (s, 3H); 
13
C NMR (75 MHz, DMSO-d6) δ: 176.82,157.5, 155.98, 150.15, 144.14, 142.29, 
135.76, 133.00, 132.49, 130.33, 129.85, 129.43, 126.84, 126.02, 125.78, 125.73, 
124.45, 121.06, 113.23, 104.88, 63.74, 61.30, 60.30, 56.31; MS-ESI: (ESI, pos.ion): 
535.1; HRMS-ESI: [M-Br
-
]
+
 calcd. For C25H20F3NO4: 456.1417, found:456.1415. 
 
(Z)-4-((7,8-dimethoxy-4-oxoisochroman-3-ylidene)methyl)-1-(2-(trifluoromethyl)b
enzyl)pyridinium bromide (1f) 
Yellow solid; 
1
H NMR (300 MHz, DMSO-d6) δ: 8.99 (d, J = 6.36 Hz, 2H), 8.50 (d, 
J = 6.36 Hz, 2H), 7.94-7.68 (m, 4H), 7.32 (m, 2H), 7.03 (s, 1H), 6.09 (s, 2H), 5.64 (s, 
2H), 3.98 (s, 3H), 3.83 (s, 3H); 
13
C NMR (75 MHz, DMSO-d6) δ: 176.80, 157.57, 
156.24, 150.56, 144.69, 142.29, 133.66, 132.51, 131.76, 130.32, 129.77, 126.88, 
126.81, 126.69, 125.78, 124.49, 121.06, 113.26, 104.76, 63.79, 60.32, 59.05, 56.33; 
MS-ESI: (ESI, pos.ion): 535.1; HRMS-ESI: [M-Br
-
]
+
 calcd. For C25H20F3NO4: 
456.1417, found: 456.1420. 
 
(Z)-1-(2,4-difluorobenzyl)-4-((7-methoxy-4-oxoisochroman-3-ylidene)methyl)pyrid
inium bromide (1g) 
Yellow solid; 
1
H NMR (300 MHz, DMSO-d6) δ: 9.02 (d, J = 6.60 Hz, 2H), 8.43 (d, 
J = 6.60 Hz, 2H), 8.00 (d, J = 9.30 Hz, 1H), 7.75 (q, J = 8.58 Hz, 1H), 7.45 (m, 1H), 
7.26 (m, 1H), 7.13 (m, 2H), 6.99 (s, 1H), 5.59 (s, 2H), 5.53 (s, 2H), 3.91 (s, 3H); 
13
C 
NMR (75 MHz, DMSO-d6) δ: 176.75, 164.47, 162.61, 156.61, 150.34, 144.15, 141.90, 
133.05, 132.97, 129.28, 126.70, 121.09, 117.99, 117.81, 115.88, 112.49, 112.25, 
108.78, 105.07, 104.74, 104.39, 67.39, 56.37, 56.01; MS-ESI: (ESI, pos.ion): 473.1; 
HRMS-ESI: [M-Br
-
]
+
 calcd. For C23H17F2NO3:394.1249, found: 394.1247 
 
(Z)-1-(2-chloro-4-fluorobenzyl)-4-((7-methoxy-4-oxoisochroman-3-ylidene)methyl
)pyridinium (1j) 
Yellow solid; 
1
H NMR (300 MHz, DMSO-d6) δ: 8.98 (d, J = 6.15 Hz, 2H), 8.44 (d, 
J = 6.15 Hz, 2H), 7.99 (m, 1H), 7.68 (m, 2H), 7.41 (m, 1H), 7.14 (s, 2H), 7.01 (s, 1H), 
5.95 (s, 2H), 5.60 (s, 2H), 3.91 (s, 3H); 
13
C NMR (75 MHz, DMSO-d6) δ: 176.71, 
164.46, 164.12, 160.79, 156.66, 150.38, 144.30, 141.90, 134.49, 133.65, 133.52, 
129.26, 128.05, 126.56, 121.08, 117.75, 117.42, 115.89, 115.42, 115.14, 108.76, 
104.71, 67.39, 59.56, 56.03; MS-ESI: (ESI, pos.ion): 489.0; HRMS-ESI: [M-Br
-
]
+
 
calcd. For C23H17ClFNO3: 410.0954, found: 410.0952. 
 
(Z)-1-benzyl-4-((4-oxoisochroman-3-ylidene)methyl)pyridinium bromide (1k) 
Yellow solid; 
1
H NMR (300 MHz, DMSO-d6) δ: 9.14 (d, J = 6.63 Hz, 2H), 8.44 (d, 
J = 6.63  Hz, 2H), 8.01 (d, J = 7.59 Hz, 1H), 7.78 (t, J = 7.20 Hz, 1H), 7.56 (m, 4H), 
7.46 (m, 3H), 7.01 (s, 1H), 5.84 (s, 2H), 5.64 (s, 2H); 
13
C NMR (75 MHz, DMSO-d6) 
δ: 178.45, 156.24, 149.91, 144.11, 139.15, 135.03, 134.55, 129.19, 128.77, 128.66, 
128.25, 127.88, 126.83, 126.41, 124.96, 105.13, 67.39, 62.29; MS-ESI: (ESI, 
pos.ion) : 407.1; HRMS-ESI: [M-Br
-
]
+
 calcd. For C22H17NO2: 328.1332, found: 
328.1332. 
 (Z)-1-(2-fluorobenzyl)-4-((4-oxoisochroman-3-ylidene)methyl)pyridinium bromide
（1l） 
Yellow solid; 
1
H NMR (300 MHz, DMSO-d6) δ: 9.06 (d, J = 6.66 Hz, 2H), 8.46 (d, 
J = 6.66 Hz, 2H), 8.01 (d, J = 7.65 Hz, 1H), 7.81 (t, J = 7.20 Hz, 1H), 7.56 (m, 4H), 
7.34 (m, 2H), 7.02 (s, 1H), 5.95 (s, 2H), 5.65 (s, 2H); 
13
C NMR (75 MHz, DMSO-d6) 
δ: 178.38, 162.05, 156.35, 150.15, 144.28, 139.11, 135.01, 132.01, 131.89, 131.33, 
128.75, 127.83, 126.76, 126.38, 125.26, 124.95, 121,51, 121.33, 116.08, 115.81, 
105.05, 67.40, 56.96; MS-ESI: (ESI, pos.ion):425.0; HRMS-ESI: [M-Br
-
]
+
 calcd. For 
C22H16FNO2: 346.1238, found: 346.1236. 
 
(Z)-1-(3-fluorobenzyl)-4-((4-oxoisochroman-3-ylidene)methyl)pyridinium bromide 
(1m) 
Yellow solid; 
1
H NMR (300 MHz, DMSO-d6) δ: 9.20 (d, J = 6.72 Hz, 2H), 8.46 (d, 
J = 6.72 Hz, 2H), 8.01 (d, J = 7.68 Hz, 1H), 7.80 (t, J = 7.47 Hz, 1H), 7.56 (m, 5H), 
7.30 (m, 1H), 7.02 (s, 1H), 5.90 (s, 2H), 5.65 (s, 2H); 
13
C NMR (75 MHz, DMSO-d6) 
δ: 178.41, 163.76, 160.51, 156.28, 150.00, 144.18, 139.13, 136.99, 136.88, 135.01, 
131.35, 131.24, 128.75, 127.85, 126.84, 126.39, 124.95, 116.29, 116.01, 115.97, 
115.68, 105.12, 67.41, 61.36; MS-ESI: (ESI, pos.ion): 425.1. HRMS-ESI: [M-Br
-
]
+
 
calcd. For C22H16FNO2: 346.1238, found: 346.1237. 
 
(Z)-1-(4-fluorobenzyl)-4-((4-oxoisochroman-3-ylidene)methyl)pyridinium bromide 
(1n) 
Yellow solid; 
1
H NMR (300 MHz, DMSO-d6) δ: 9.14 (d, J = 6.78 Hz, 2H), 8.44 (d, 
J = 6.78 Hz, 2H), 8.01 (d, J = 7.59 Hz, 1H), 7.83 (t, J = 6.63 Hz, 1H), 7.71-7.54 (m, 
4H), 7.32 (t, J = 8.82 Hz, 2H), 7.01 (s, 1H), 5.84 (s, 2H), 5.64 (s, 2H); 
13
C NMR (75 
MHz, DMSO-d6) δ: 178.42, 164.11, 160.84, 156.25, 149.93, 144.02, 139.14, 135.03, 
131.38, 131.26, 130.77, 128.77, 127.87, 126.83, 126.41, 124.96, 116.22, 115.93, 
105.12, 67.40, 61.40; MS-ESI: (ESI, pos.ion):425.1; HRMS-ESI: [M-Br
-
]
+
 calcd. For 
C22H16FNO2: 346.1238, found: 346.1238. 
 
(Z)-1-benzyl-4-((6,7-dimethoxy-4-oxoisochroman-3-ylidene)methyl)pyridinium 
bromide (1o) 
Yellow solid； 1H NMR (300 MHz, DMSO-d6) δ: 9.12 (d, J = 5.91 Hz, 2H), 8.42 (d, 
J = 5.91 Hz, 2H), 7.58-7.40 (m, 6H), 7.15 (s, 1H), 6.96 (s, 1H), 5.85 (s, 2H), 5.55 (s, 
2H), 3.91 (s, 3H), 3.85 (s, 3H); 
13
C NMR (75 MHz, DMSO-d6) δ: 176.34, 156.21, 
154.93, 150.08, 149.11, 143.96, 134.66, 134.60, 129.18, 128.65, 126.65, 120.63, 
107.25, 107.02, 104.55, 67.11, 62.16, 56.26, 55.66; MS-ESI: (ESI, pos.ion): 467.1; 
HRMS-ESI: [M-Br
-
]
+
 calcd. For C24H21NO4: 388.1543, found: 388.1544. 
 
(Z)-4-((6,7-dimethoxy-4-oxoisochroman-3-ylidene)methyl)-1-(3-fluorobenzyl)pyri
dinium bromide (1p) 
Yellow solid; 
1
H NMR (300 MHz, DMSO-d6) δ: 9.13 (d, J = 6.27 Hz, 2H), 8.44 (d, 
J = 6.27 Hz, 2H), 7.54-7.30 (m, 5H), 7.15 (s, 1H), 6.98 (s, 1H), 5.86 (s, 2H), 5.56 (s, 
2H), 3.91 (s, 3H), 3.86 (s, 3H); 
13
C NMR (75 MHz, DMSO-d6) δ: 176.37, 163.77, 
160.53, 156.31, 154.96, 150.24, 149.15, 144.06, 136.92, 134.68, 131.36, 131.25, 
126.69, 124.89, 120.67, 116.28, 115.99, 115.91, 115.62, 107.31, 107.04, 104.55, 67.13, 
61.38, 56.27, 55.68; MS-ESI: (ESI, pos.ion):485.1; HRMS-ESI: [M-Br
-
]
+
 calcd. For 
C24H20FNO4:406.1449, found: 406.1450. 
 
(Z)-4-((6,7-dimethoxy-4-oxoisochroman-3-ylidene)methyl)-1-(4-fluorobenzyl)pyri
dinium bromide (1q) 
Yellow solid； 1H NMR (300 MHz, DMSO-d6) δ: 9.11 (d, J = 6.81 Hz, 2H), 8.42 (d, 
J = 6.27 Hz, 2H), 7.67 (m, 2H), 7.41 (s, 1H), 7.32 (t, J = 8.88 Hz, 2H), 7.15 (s, 1H), 
6.97 (s, 1H), 5.83 (s, 2H), 5.56 (s, 2H),3.91 (s, 3H), 3.86 (s, 3H); 
13
C NMR (75 MHz, 
DMSO-d6) δ: 176.37, 164.09, 160.83, 156.25, 154.95, 150.13, 149.13, 143.88, 134.66, 
131.35, 131.23, 130.78, 126.66, 120.66, 116.21, 115.93, 107.29, 107.04, 104.55, 
67.12, 61.29, 56.26, 55.68; MS-ESI: (ESI, pos.ion): 485.1; HRMS-ESI: [M-Br
-
]
+
 
calcd. For C24H20FNO4: 406.1449, found: 406.1452. 
 
(Z)-4-((6,7-dimethoxy-4-oxoisochroman-3-ylidene)methyl)-1-(2-fluorobenzyl)pyri
dinium bromide (1r) 
Yellow solid;
 1
H NMR (300 MHz, DMSO-d6) δ: 9.06 (s, 2H), 8.45 (s, 2H), 
7.67-6.97 (m, 7H), 5.97 (s, 2H), 5.57 (s, 2H), 3.91 (s, 3H), 3.86 (s, 3H); 
13
C NMR (75 
MHz, DMSO-d6) δ: 176.27, 162.07, 158.79, 156.33, 154.93, 150.33, 149.09, 144.16, 
134.66, 131.99, 131.89, 131.34, 126.58, 125.23, 121.59, 121.41, 120.59, 116.08, 
115.81, 107.24, 107.07, 104.49, 67.14, 56.79, 56.29, 55.66; MS-ESI: (ESI, 
pos.ion):485.1; HRMS-ESI: [M-Br
-
]
+
 calcd. For C24H20FNO4: 406.1449, found: 
406.1456. 
1-benzyl-4-((7,8-dimethoxy-4-oxoisochroman-3-yl)methyl)pyridinium bromide（1s） 
Yellow solid；1H NMR (300 MHz, CDCl3) δ: 9.54 (d, J = 6.36 Hz, 2H), 7.94 (d, J = 
6.36 Hz, 2H), 7.75 (m, 3H), 7.33 (m, 3H), 6.94 (d, J = 8.76 Hz, 1H), 6.25 (s, 2H), 
5.07 (d, J = 15.81 Hz, 1H), 4.74 (d, J = 15.81 Hz, 1H), 4.44 (m, 1H), 3.94 (s, 3H), 
3.82 (s, 3H), 3.60(m, 1H), 2.29 (m, 1H); 
13
C NMR (75 MHz, DMSO-d6) δ: 192.18, 
159.23, 157.00, 143.79, 142.62, 135.42, 134.43, 129.34, 129.21, 128.87, 123.62, 
122.14, 112.10, 79.09, 62.43, 60.14, 56.12, 35.07; MS-ESI: (ESI, pos.ion): 469.1. 
HRMS-ESI: [M-Br
-
]
+
 calcd. For C24H23NO4 : 390.0996, found: 390.0994. 
 
4-((7,8-dimethoxy-4-oxoisochroman-3-yl)methyl)-1-(4-fluorobenzyl)pyridinium 
bromide (1t) 
Yellow solid; 
1
H NMR (300 MHz, DMSO-d6) δ: 9.20 (d, J = 6.51 Hz, 2H), 8.15 (d, 
J = 6.51 Hz, 2H), 7.72 (m, 3H), 7.32 (t, J = 8.79 Hz, 1H), 7.20 (d, J = 8.76 Hz, 1H), 
5.86 (s, 2H), 5.04-4.79 (m, 3H), 3.93 (s, 3H), 3.77 (s, 3H), 3.60(m, 1H), 2.29 (m, 1H); 
13
C NMR (75 MHz, DMSO-d6) δ: 192.18, 164.17, 160.91, 159.25, 157.00, 143.71, 
142.62, 135.41, 131.58, 131.46, 130.64, 128.88, 123.63, 122.14, 116.27, 115.98, 
112.09, 79.09, 62.43, 61.57, 60.13, 56.11, 35.06; MS-ESI: (ESI, pos.ion): 487.1; 
HRMS-ESI: [M-Br
-
]
+
 calcd. For C24H22FNO4: 408.1606, found: 408.1672. 
 
4-((7,8-dimethoxy-4-oxoisochroman-3-yl)methyl)-1-(3-fluorobenzyl)pyridinium 
bromide (1u) 
Yellow solid; 
1
H NMR (300 MHz, DMSO-d6) δ: 9.25 (s, 2H), 8.17 (s, 2H), 
7.76-7.20 (m, 6H), 5.91 (s, 2H), 4.91 (m, 3H), 3.92 (s, 3H), 3.74 (s, 3H), 3.63 (m, 1H), 
2.27 (m, 1H); 
13
C NMR (75 MHz, DMSO-d6) δ: 192.18, 163.73, 160.48, 159.39, 
157.00, 143.88, 142.61, 136.80, 136.70, 135.42, 131.40, 131.29, 128.90, 125.12, 
123.63, 122.13, 116.42, 116.15, 115.85, 112.09, 79.07, 62.43, 61.58, 60.13, 56.11, 
35.09; MS-ESI: (ESI, pos.ion): 487.1; HRMS-ESI: [M-Br
-
]
+
 calcd. For C24H22FNO4: 
408.1606, found: 408.1603. 
 
4-((7,8-dimethoxy-4-oxoisochroman-3-yl)methyl)-1-(2-fluorobenzyl)pyridinium 
bromide (1v) 
Yellow solid； 1H NMR (300 MHz, DMSO-d6) δ: 9.18 (d, J = 6.30 Hz, 2H), 8.20 (d, 
J = 6.30 Hz, 2H), 7.75 (d, J = 6.27 Hz, 2H), 7.58 (m, 1H), 7.53 (m, 2H), 7.22 (d, J = 
8.76 Hz, 1H), 6.04 (s, 2H), 505-4.85 (m, 3H), 3.93 (s, 3H), 3.75 (s, 3H), 3.63 (m, 1H), 
2.53 (m, 1H); 
13
C NMR (75 MHz, DMSO-d6) δ: 192.18, 162.13, 159.57, 144.25, 
142.59, 135.42, 132.15, 131.60, 128.88, 126.69, 125.28, 124.47, 123.62, 122.13, 
116.12, 115.85, 112.09, 79.06, 62.45, 60.33, 60.14, 57.03, 56.13, 35.12; MS-ESI: (ESI, 
pos.ion): 487.1. HRMS-ESI: [M-Br
-
]
+
 calcd. For C24H22FNO4: 408.1606, found: 
408.1604. 
 
(Z)-6,7-dimethoxy-3-(pyridin-4-ylmethylene)isochroman-4-one 
White solid;
 1
H NMR (300 MHz, DMSO-d6) δ: 8.61 (m, 2H), 7.66 (m, 2H), 7.57 (s, 
1H), 6.89 (s, 1H), 6.67 (s, 1H), 5.30 (s, 2H), 3.99 (s, 3H) , 3.98 (s, 3H); MS-ESI: (ESI, 
pos.ion): 298.1. 
 
(Z)-3-(pyridin-4-ylmethylene)isochroman-4-one 
Yellow solid; 
1
H NMR (300 MHz, CDCl3) δ: 8.63 (m, 2H), 8.12 (d, J = 7.65 Hz, 
2H), 7.65 (m, 3H), 7.51 (t, J = 7.32 Hz, 1H), 7.30 (m, 1H), 6.25 (s, 2H), 6.91 (s, 1H), 
5.35 (s, 2H); MS-ESI: (ESI, pos.ion): 238.1. 
 
AChE and BuChE inhibitory activity test assay 
The compound was dissolved in DMSO, diluted with buffer A to the desired 
concentration, and the DMSO content in the solution was controlled to be less than 
1%. To the 96-well plates were added: 160 μL of 1.5 mM DTNB, 50 μL of AChE 
(0.22 U/mL, prepared with Buffer B) and 10 μL of different concentrations of 
inhibitor, incubated at 37 °C for 10 min, and then 30 μL of iodoacetylcholine (15 mM) 
was added rapidly. The absorbance changes of 0, 60, 120 and 180 s were measured at 
405 nM wavelengths. BuchE was tested in an assay similar to AChE, which needed to 
replace AChE with BuChE (0.12 U/mL, prepared with Buffer B) and replace substrate 
iodoacetylcholine with thioiodobenzoyl chloride (15 mM), other conditions remain 
unchanged. 
 
Cell viability 
SH-SY5Y cells were planted in a 25 mL culture flask containing 1: 1 mixture of 
Eagle's minimum essential medium (EMEM) and ham's F-12 medium supplemented 
with 10% fetal bovine serum, 100 U/mL penicillin and 100 μg/mL streptomycin, 
placed in a 5% carbon dioxide incubator at 37 °C. The cells were then grown at a 
density of 10,000 per well in 96-well plates. When the cells were fused, the cells were 
placed in serum-free medium and cultured with different concentrations of compound 
1q, 1r (1, 5, 10, 25, 50 μM) for 24 h. After completion of the incubation, 20 μL of 
MTT was added at 37 °C for 4 h, and 200 μL of DMSO was added to dissolve 
methanine crystals at the end, and the absorbance was measured at 570 nM. 
 
Plasma stability test 
A certain amount of compound 1q was dissolved in DMSO, which was adjusted to 
the equivalent of free base 1.67 mg/mL of the mother liquor according to the purity 
and salinity, and then using 50% MeOH diluted it to 100 μg/mL of the INT solution.  
2 μL of INT solution was took and mixed with 998 μL plasma (n = 2, the ratio of 
organic phase in the system does not exceed 0.5%), and the concentration of 
compound in plasma is 200 mg/mL, it was placed at 37 °C water bath incubation. The 
sampling point was set at 0 min, 10 min, 30 min, 1 h, 2 h. each sampling point took 
100 μL of sample  and was added 300 μL acetonitrile  to precipitate, then 
centrifuged at 12,000 rpm for 5 min,  supernatant 100 μL was added 100 μL 0.1% 
formic acid and took to LC-MS/MS analysis. 
 
Determination of pharmacokinetic parameters 
Three male Sprague-Dawley (SD) rats (200-220 g) were dosed with 1q 
intravenously (i.v.) at dose of 1 mg/kg following Institutional Animal Care and Use 
Committee guidelines. The compound was dissolved in a vehicle of 5% DMA, 10% 
Solutol HS-15 and 85% saline. Blood samples (0.3 mL) were obtained via orbital 
sinus puncture at 5 min, 15 min, 30 min, 1 h, 2 h, 4 h, 6 h, 8 h, 10 h, and 24 h time 
points and collected into heparinized tubes. Blood samples were centrifuged for cell 
removal, and the plasma supernatant was then transferred to a clean vial and 
subsequently stored in 4 
o
C prior to analysis. Test sample concentrations were 
determined by LC-MS/MS (Agela Technologies Venusil XBP C8(L) 2.1*5mm, 5µm, 
150A) using propranolol as an internal standard. Pharmacokinetic parameters were 
calculated using winnonlin 5.2. software. 
 
Results and discussion 
To determine the inhibitory activities of these target compounds against AChE and 
BuChE
13
, IC50 of all compounds were obtained. Lead compound 1 and donepezil were 
used as the reference compounds, and the results were shown in Table 1. It was found 
that the inhibitory activities of most compounds reached the nanomolar level against 
AChE and the micromolar level against BuChE. Among them, compound 1q showed 
the most potent activity against AChE with IC50 of 0.15 nM, which was 250 and 160 
times higher compared to the positive drug donepezil and the lead compound 1, 
respectively. Furthermore, its selectivity index of AChE/BuChE reached up to 5903. 
The SARs studies showed that when keeping fluorine group at the para-position of 
the benzyl group, the anti-AChE activity was enhanced or maintained by introducing 
halogens to the ortho-position. On the contrast, introducing halogens to the 
meta-position decreased the activity dramatically. As to compounds 1o-1r, the 
number and position of the methoxy group on 4-isochromanone skeleton had a 
significant influence on the anticholinesterase activity. The compounds bearing 
methoxy group at both R1 and R2 positions exhibited more potent anticholinesterase 
activity than those with methoxy group at both R2 and R3 positions. Besides, those 
compounds with reduced double bond also have good anticholinesterase activity 
(1s-1v). 
 
Molecular docking study 
In order to investigate the interaction mode of compounds 1 and 1q with AChE, a 
molecular modeling study
14
 was carried out by using Molecular Operating 
Environment (MOE) software and the PDB structure of 1EVE was taken from the 
RCSB Protein Data Bank for the docking procedure. Previous studies showed that 
two methoxy groups of donepezil interacted with Trp286 of acetylcholinesterase 
through hydrogen bond
15,16
. In the present study, the methoxy group at the C7 position 
of compound 1 interacted with Trp286 to form a hydrogen bond, while the methoxy 
group at the C8 position could not form a hydrogen bond with Trp286 due to steric 
hindrance (Figure 2b). However, both methoxy groups of compound 1q could 
interacted with Trp286 through hydrogen bond, which was similar to that of donepezil, 
and at the same time, according to previous study, phenyl pyridine interacted with the 
CAS of AChE and the 4-isochromanone moiety interacted with the PAS of the AChE 
simultaneously. This interaction mode might explain why the activity of compound 
1q was significantly increased. 
 Figure 2. (a) 3D docking graph of compound 1; (b) 2D docking graph of compound 1; 
(c) 3D docking graph of compound 1q; (d) 2D docking graph of compound 1q. 
 
Cell viability test of compounds 1q and 1r 
To measure the toxicity of target compounds against nerve cells
17
, the viability of 
SH-SY5Y cells treated with representative compounds 1q and 1r was determined and 
the result was shown in Table 2. When SH-SY5Y cells were exposed to compounds 
1q and 1r at concentrations of 5 and 50 μM for 24 h, the survival rates of nerve cells 
did not decrease obviously. Even at the concentration of 100 μM, the survival rate just 
decreased slightly (cell viability >90%) and the morphology of the cells was not 
affected, indicating the low toxicity of these compounds.   
 
Table 2. Cell viability of compounds 1q and 1r on nerve cells SH-SY5Y 
Compound Concentrations (μM) Cell viability (%) 
1q 
5 98.3 ± 12.1 
50 97.8 ± 15.2 
100 93.4 ± 10.2 
1r 
5 97.8 ± 11.5 
50 97.6 ± 15.2 
100 91.4 ± 13.1 
 
Plasma stability test and pharmacokinetic data of compound 1q 
Compound 1q has a good inhibitory activity on enzyme, in order to provide 
information for pharmacokinetic evaluation, representative compound 1q was 
selected for preliminary plasma stability test. The results showed the concentration of 
compound 1q in plasma decreased with time, but changed slightly in the period of 0 
to 2 h, indicating that compound 1q was relatively stable in rat plasma (Table 3).  
 
Table 3. Plasma stability test of compound 1q 
Time 
Analyte Peak Area 
(counts) 
IS Peak Area 
(counts) 
Area Ratio 
0 min 3.46E+05 3.12E+05 1.11E+00 
10min 3.41E+05 2.79E+05 1.22E+00 
30min 3.34E+05 2.76E+05 1.21E+00 
1 h 3.04E+05 2.58E+05 1.18E+00 
2 h 2.84E+05 2.55E+05 1.11E+00 
 
The further pharmacokinetic evaluation showed that compound 1q had undesirable 
pharmacokinetic properties and its average half-life was only 1.94 hours (Table 4). 
Therefore, compound 1q might be considered as a promising lead for the next round 
structural modification. 
 
Table 4. Pharmacokinetic parameters (mean ± S.D) of 1q（1.0 mg/kg, i.v.）in rats 
(n=3) 
HL.Lambda_z(h) Tmax 
(h) 
Cmax 
(ng/ml) 
AUClast 
(h*ng/ml) 
AUCinf 
(h*ng/ml) 
Vz_obs 
(ml/kg) 
Cl_obs 
(ml/h/kg) 
MRTlast 
(h) 
1.94 ± 0.05 0.083 ±0.0 3947 ±311 2460 ±182 2465 ±182 1139 ±116 407 ±31 0.70 ±0.03 
Note: The pharmacokinetic parameters were calculated using winnonlin 5.2. 
HL: half life of the drug 
Tmax: the time to reach the peak concentration of drug  
Cmax: peak concentration of drug  
     AUC: area under the curve, it is an important indicator of the degree of drug absorption 
     Vz: apparent distribution volume 
Cl: drug internal clearance rate 
MRT: average dwell time 
 
Conclusions  
In conclusion, a series of novel AChE inhibitors derived from natural product XJP 
were further designed and synthesized based on our previous studies. The biological 
evaluation showed that these compounds had potent activities against AChE and good 
selectivity against BuChE. Among them, compound 1q showed the strongest 
anti-AChE activity (IC50 = 0.15 nM), high AChE/BuChE selectivity (SI >5903) and 
low neurotoxicity. Additionally, compound 1q possessed high plasma stability. As a 
result, compound 1q might be considered as a promising lead compound for further 
research to develop new anti-AD agents.  
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